The present invention relates to the use of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, solids forms, and pharmaceutical compositions thereof for the treatment of CFTR mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations.
本发明涉及使用N-[2,4-双(
1,1-二甲基乙基)-5-羟基苯基]-1,4-二氢-4-氧
喹啉-3-羧酰胺,其固体形式和制药组合物,用于治疗CFTR介导的疾病,特别是在患有特定遗传突变的患者中治疗囊性纤维化症。